4.7 Article

Foeniculum vulgare seed extract exerts anti-cancer effects on hepatocellular carcinoma

期刊

FOOD & FUNCTION
卷 12, 期 4, 页码 1482-1497

出版社

ROYAL SOC CHEMISTRY
DOI: 10.1039/d0fo02243h

关键词

-

资金

  1. National Natural Science Foundation of China [81771947, 31371425]
  2. Liaoning Provincial Natural Science Foundation of China [20180551061]

向作者/读者索取更多资源

The Foeniculum vulgare extract has shown anti-cancer effects on HCC cells by reducing cell viability, inducing apoptosis, and inhibiting cell migration. Studies in nude mice also demonstrated significant inhibition of HCC growth. Mechanistic analyses suggest that the extract targets the oncoprotein survivin, sensitizing HCC cells to apoptosis while sparing normal liver cells.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. The prognosis of HCC is very poor due to the absence of symptoms and a lack of effective treatments. Studies have shown that various Foeniculum vulgare (fennel) extracts exhibit anti-cancer effects on malignant tumors such as skin cancer and prostate cancer. However, the anti-tumor activity of Foeniculum vulgare and its underlying molecular mechanisms towards HCC are unknown. Here, we provide fundamental evidence to show that the 75% ethanol extract of Foeniculum vulgare seeds (FVE) reduced cell viability, induced apoptosis, and effectively inhibited cell migration in HCC cells in vitro. HCC xenograft studies in nude mice showed that FVE significantly inhibited HCC growth in vivo. Mechanistic analyses showed that FVE reduced survivin protein levels and triggered mitochondrial toxicity, subsequently inducing caspase-3 activation and apoptosis. Survivin inhibition effectively sensitized HCC cells to FVE-induced apoptosis. Moreover, FVE did not induce a decrease in survivin or apoptotic toxicity in normal liver cells. Collectively, in vivo and in vitro results suggest that FVE exerts inhibitory effects in HCC by targeting the oncoprotein survivin, suggesting FVE may be a potential anti-cancer agent that may benefit patients with HCC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据